Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NYXOAH ANNOUNCES ISSUANCE OF FIRST TRANCHE OF CONVERTIBLE BONDS MONT-SAINT-GUIBERT, BELGIUM  DECEMBER 19, 2025, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE SOLUTIONS TO TREAT OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED THE ISSUANCE OF THE FIRST TRANCHE OF THE CONVERTIBLE BOND FINANCING ENTERED INTO WITH AN ENTITY MANAGED BY HEIGHTS CAPITAL MANAGEMENT (HCM) OF UP TO 45 MILLION, AS PREVIOUSLY ANNOUNCED BY THE COMPANY ON NOVEMBER 13, 2025. CLOSING OF THE FIRST TRANCHE OF THE CONVERTIBLE BONDS' ISSUANCE ON DECEMBER 18, 2025, THE COMPANY ISSUED THE FIRST TRANCHE OF CONVERTIBLE BONDS FOR A NOMINAL AMOUNT OF 22.5 MILLION UNDER THE SUBSCRIPTION AGREEMENT ENTERED INTO WITH HCM ON NOVEMBER13, 2025, AS AMENDED AND RESTATED ON DECEMBER 16, 2025.

NYXOAH ANNOUNCES ISSUANCE OF FIRST TRANCHE OF CONVERTIBLE BONDS

NYXOAH ANNOUNCES COMMERCIAL LAUNCH OF GENIO BREAKTHROUGH THERAPY IN THE NETHERLANDS FIRST GENIO IMPLANTS SUCCESSFULLY PERFORMED AT OLVG WEST AND ZUYDERLAND HOSPITALS

NYXOAH ANNOUNCES COMMERCIAL LAUNCH OF GENIO BREAKTHROUGH THERAPY IN THE NETHERLANDS

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), DECEMBER 2, 2025 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE ACT OF 2 MAY 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED TWO TRANSPARENCY NOTIFICATIONS AS DETAILED BELOW. ROBERT TAUB / BMI ESTATE ON NOVEMBER 27, 2025, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM ROBERT TAUB AND RELATED PERSON BMI ESTATE.

PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS

NYXOAH TO PARTICIPATE IN THE PIPER SANDLER 37 TH ANNUAL HEALTHCARE CONFERENCE

NYXOAH TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

NYXOAH'S GENIO THERAPY RECEIVES SIGNIFICANT 2026 MEDICARE REIMBURSEMENT INCREASES UNDER FINAL CMS RULE ASSIGNMENT TO NEW TECHNOLOGY APC 1580 IS POSITIVE NEWS FOR NYXOAH'S U.S. COMMERCIAL ROLLOUT BY STRENGTHENING HOSPITAL AND ASC ECONOMICS MONT-SAINT-GUIBERT, BELGIUM  NOVEMBER 26, 2025, 7:45 AM CET / 1:45 AM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED THAT THE U.S. CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) HAS FINALIZED ITS CY2026 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (HOPPS) AND AMBULATORY SURGERY CENTER (ASC) RULE. WITHIN THE FINAL RULE, CMS ASSIGNED CPT CODE 64568, THE CODE USED FOR ALL GENIO HYPOGLOSSAL NERVE STIMULATION (HGNS) IMPLANTS, TO NEW TECHNOLOGY AMBULATORY PAYMENT CLASSIFICATION (APC) 1580.

NYXOAH'S GENIO THERAPY RECEIVES SIGNIFICANT 2026 MEDICARE REIMBURSEMENT INCREASES UNDER FINAL CMS RULE

REGULATED INFORMATION INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MONT-SAINT-GUIBERT (BELGIUM), NOVEMBER 20, 2025 , 10:30PMCET / 4:30PMET  IN ACCORDANCE WITH ARTICLE 15 OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS AND NASDAQ:NYXH) PUBLISHES THE BELOW INFORMATION FOLLOWING THE ISSUE OF NEW SHARES. SHARE CAPITAL: EUR 6.504.688,76 TOTAL NUMBER OF SECURITIES CARRYING VOTING RIGHTS: 43,026,460 (ALL ORDINARY SHARES) TOTAL NUMBER OF VOTING RIGHTS (= DENOMINATOR): 43,026,460 (ALL RELATING TO ORDINARY SHARES) NUMBER OF RIGHTS TO SUBSCRIBE TO SECURITIES CARRYING VOTING RIGHTS NOT YET ISSUED: 3,258,819 (ALL GRANTED SUBSCRIPTION RIGHTS; THIS NUMBER EXCLUDES 692,677 SUBSCRIPTION RIGHTS THAT WERE ISSUED BUT NOT YET GRANTED) * * * CONTACT: NYXOAH JOHN LANDRY, CFOIR@NYXOAH.COM ATTACHMENT 2025 11 20 - PRESS RELEASE - NUMBER OF SHARES (ENG)

INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES

INSIDE INFORMATION REGULATED INFORMATION NYXOAH SECURES FINANCING COMMITMENTS OF UP TO U.S. $77 MILLION TO DRIVE U.S. COMMERCIALIZATION OF GENIO FINANCINGS ARE COMPRISED OF EQUITY INVESTMENTS, INCLUDING FROM COCHLEAR, RESMED AND NYXOAH'S CHAIRMAN AND MANAGEMENT, AND A CONVERTIBLE BOND. MONT-SAINT-GUIBERT, BELGIUM  NOVEMBER 13, 2025, 2025, 10:11PM CET / 4:11 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE SOLUTIONS TO TREAT OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED A 22 MILLION PRIVATE PLACEMENT OF EQUITY, A U.S. $5.6 MILLION REGISTERED DIRECT OFFERING, AND A 17 MILLION REGISTERED DIRECT OFFERING COMBINED WITH A CONVERTIBLE BOND FINANCING OF UP TO 45 MILLION.

NYXOAH SECURES FINANCING COMMITMENTS OF UP TO U.S. $77 MILLION TO DRIVE U.S. COMMERCIALIZATION OF GENIO

REGULATED INFORMATION NYXOAH REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS US LAUNCH OFF TO A STRONG START. FIRST COMMERCIAL GENIO IMPLANTS COMPLETED WITH WIDESPREAD PAYER COVERAGE DRIVES INITIAL REVENUE.

NYXOAH REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

NYXOAH TO PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE MONT-SAINT-GUIBERT, BELGIUM  NOVEMBER 3, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE ON TUESDAY, NOV. 11, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 9:20AM EASTERN TIME THE SAME DAY VIA WEBCAST.

NYXOAH TO PARTICIPATE IN THE STIFEL 2025 HEALTHCARE CONFERENCE

NYXOAH TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

Nyxoah S.A.

NYXH

Price

Financial Reports

No items found.

Press Releases

Nyxoah S.A.

NYXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NYXH